A Phase 1b Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of MYC Oncogene Overexpression
Latest Information Update: 23 Sep 2022
At a glance
- Drugs Dinaciclib (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 16 Sep 2022 Status changed from active, no longer recruiting to completed.
- 13 Jul 2020 Planned End Date changed from 1 Jun 2020 to 31 Dec 2022.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology